La cadena de opciones muestra datos clave de las opciones de acciones de Coterra Energy a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Coterra Energy..

Coterra Energy (NYSE:CTRA) Bolsa, Cadena de Opciones

COTERRA ENERGY INC

Coterra Energy

Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.

Coterra Energy Inc

Valvoline Receives Second Request From Federal Trade Commission For Additional Information About The Proposed Acquisition Of Breeze Autocare

News

Contracts

Movers

Trading Ideas

BON Wins $12M 24-Month Supply Agreement To Co-Develop Apple Polyphenol-Infused Health Solutions

Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRBW#NASDAQ">NTRBW</a>), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA&#x2122; abuse deterrent transdermal technology.
The Macao Intellectual Property Office granted patent J/9010 on February 11, 2025 as recorded in Macao Official Bulletin No. 10 on March 5, 2025. Macao is a Special Administrative Region (SAR) of the People's Republic of China that has its own patent system and patent laws which are separate and distinct from those of mainland China.
The AVERSA&#x2122; abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia as well as two regions of China: Hong Kong and Macao.
Nutriband's AVERSA&#x2122; abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA&#x2122; abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband is currently working with its partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA&#x2122; Fentanyl, which incorporates Nutriband's AVERSA&#x2122; abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.

Government

Regulations

NTRB

NTRBW

Nutriband Secures Macao Patent for AVERSA, Expanding Global Protection for Abuse-Deterrent Opioid Patch, Eyes Up to $200M in Peak US Sales

Mizuho analyst David Belinger initiates coverage on Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform rating and announces Price Target of $105.

Price Target

Initiation

Analyst Ratings

Mizuho Initiates Coverage On Walmart with Outperform Rating, Announces Price Target of $105

General

ITGR

Integer Holdings Issues Statement On Tariffs, Says 'We continue to estimate an impact of $1 to $5 million on full year adjusted operating income, consistent with previous communications.'

Mizuho analyst David Belinger initiates coverage on Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Neutral rating and announces Price Target of $975.

COST

Mizuho Initiates Coverage On Costco Wholesale with Neutral Rating, Announces Price Target of $975

VERV

Verve Therapeutics Receives FDA Fast Track Designation For Its VERVE-102 In Vivo Base Editing Medicine Targeting PCSK9

Biotech

CATX

Perspective Therapeutics Doses First Patient With [212Pb]VMT01 Monotherapy At 1.5 mCi In Phase 1/2a Study Of MC1R-Positive Metastatic Melanoma

Mizuho analyst David Belinger initiates coverage on Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral rating and announces Price Target of $92.

Mizuho Initiates Coverage On Target with Neutral Rating, Announces Price Target of $92

WIIM

JPMorgan Chase shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.

Morgan Stanley analyst Kristine Liwag downgrades Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) from Overweight to Equal-Weight and lowers the price target from $10 to $7.

Downgrades

JOBY

Morgan Stanley Downgrades Joby Aviation to Equal-Weight, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) with a Buy and maintains $7.5 price target.

Reiteration

UNCY

HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $7.5 Price Target

Earnings

JPMorgan Chase CEO Jamie Dimon: "The economy is facing considerable turbulence (including geopolitics), with the potential positives of tax reform and deregulation and the potential negatives of tariffs and "trade wars," ongoing sticky inflation, high fiscal deficits and still rather high asset prices and volatility."

Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.96 billion which beat the analyst consensus estimate of $1.95 billion by 0.45 percent. This is a 3.38 percent increase over sales of $1.90 billion the same period last year.

Earnings Beats

FAST

Fastenal Q1 2025 GAAP EPS $0.52, Inline, Sales $1.96B Beat $1.95B Estimate

Keefe, Bruyette &amp; Woods analyst Brady Gailey maintains Bank7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) with a Outperform and lowers the price target from $50 to $47.

BSVN

Keefe, Bruyette & Woods Maintains Outperform on Bank7, Lowers Price Target to $47

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy and maintains $19 price target.

CADL

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported quarterly earnings of $5.07 per share which beat the analyst consensus estimate of $4.62 by 9.74 percent. This is a 14.19 percent increase over earnings of $4.44 per share from the same period last year. The company reported quarterly sales of $46.014 billion which beat the analyst consensus estimate of $44.111 billion by 4.31 percent. This is a 8.15 percent increase over sales of $42.548 billion the same period last year.

JPMorgan Chase Q1 2025 GAAP EPS $5.07 Beats $4.62 Estimate, Sales $46.014B Beat $44.111B Estimate

Wells Fargo Q1 net Interest Income Decreased 6%, Driven By The Impact Of Lower Interest Rates On Floating Rate Assets, Deposit Mix And Pricing Changes, Lower Loan Balances, And One Fewer Day In The Quarter, Partially Offset By Lower Market Funding

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.

LUCD

Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

Goldman Sachs analyst Noah Poponak downgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowers the price target from $150 to $109.

Goldman Sachs Downgrades Booz Allen Hamilton to Neutral, Lowers Price Target to $109

Press Releases

Coterra Energy to Participate at Upcoming Conference

Coterra Announces Accretive Permian Basin Acquisitions

Coterra Energy Announces Pricing of $1.5 Billion of Senior Unsecured Notes

Coterra Energy and Halliburton Launch First Fully Automated Hydraulic Fracturing Program

Coterra Energy Closes Previously Announced Permian Basin Acquisitions

Coterra Energy Schedules Fourth-Quarter and Full Year 2024 Results Conference Call for Tuesday, February 25, 2025

Dan O. Dinges and Robert S. Boswell to Retire from Coterra Energy Board of Directors

Coterra Energy Reports 2024 Results, Provides 2025 Guidance and Updated Three-Year Outlook, and Announces Dividend Increase

Coterra Energy Announces Planned Executive Retirements

Coterra Energy Schedules First-Quarter 2025 Results Conference Call for Tuesday, May 6, 2025

CTRA

Antero Resources Corporation Common Stock

Antero Resources

Black Stone Minerals, L.P. Common units representing limited partner interests

Black Stone Minerals

Chord Energy

CNX Resources

ConocoPhillips

California Resources Corporation Common Stock

California Resources

Comstock Resources

Devon Energy

EOG Resources

Expand Energy

Diamondback Energy

Gulfport Energy Corporation Common Shares

Gulfport Energy

Hess

Magnolia Oil & Gas Corporation Class A Common Stock

Magnolia Oil & Gas

Matador Resources

Ovintiv

Permian Resources Corporation Class A Common Stock

Permian Resources

Range Resources

Texas Pacific Land Corporation Common Stock

Texas Pacific Land

Venture Global, Inc. Class A common stock

Venture Global

Vista Energy S.A.B. de C.V. American Depositary Shares, each representing one series A share, with no par value

Vista Energy

Viper Energy, Inc. - Class A Common Stock

Viper Energy

Woodside Energy Group Limited American Depositary Shares, each representing one Ordinary Share

Comments

Coterra Energy

Coterra Energy (CTRA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL